Key clinical point: Immune checkpoint inhibitors may be less effective if the patient is receiving corticosteroids at the time treatment is started.
Major finding: Corticosteroid use at the time of PD-1/PD-L1 blockade was associated with decreased progression-free survival (hazard ratio, 1.31; P = .03) and overall survival (HR, 1.66; P less than .001) in multivariate analysis.
Study details: Retrospective analysis of 640 patients treated with atezolizumab, durvalumab, nivolumab, or pembrolizumab at Memorial Sloan Kettering Cancer Center or Gustave Roussy Cancer Center.
Disclosures: The authors reported disclosures related to Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Genentech, Janssen Pharmaceuticals, MedImmune, Merck, Mirati Therapeutics, Pfizer, Roche, Shattuck Labs, and Syndax, among others.
Arbour KC et al. J Clin Oncol. 2018 Aug 20. doi: 10.1200/JCO.2018.79.0006.